Probiotics and colon cancer

Department of Medical Nutrition, Karolinska Institute, Novum, S-141 86, Huddinge, Sweden.
Baillière&#x027 s Best Practice and Research in Clinical Gastroenterology (Impact Factor: 3.48). 11/2003; 17(5):849-59. DOI: 10.1016/S1521-6918(03)00056-8
Source: PubMed


Although a myriad of health-promoting effects have been attributed to the probiotic lactic acid bacteria, perhaps the most interesting and controversial is that of anticancer activity, the vast majority of studies in this area dealing with protective effects against colon cancer. There is no direct experimental evidence for cancer suppression in humans as a result of the consumption of probiotic cultures in fermented or unfermented dairy products, but there is a wealth of indirect evidence, based largely on laboratory studies. Reports in the literature regarding the anticancer effects of lactic acid bacteria fall into the categories of in vitro studies, animal studies, epidemiological studies and human dietary intervention studies. Examples of these reports will be given in the current paper. The mechanisms by which probiotic bacteria may inhibit colon cancer are still poorly understood, but, several potential mechanisms are being discussed in the literature, and these will also be addressed in this review.

9 Reads
  • Source
    • "Probiotics are live microorganisms that provide health benefits on the host when administered in sufficient amounts (Wang et al., 2012). Yogurts containing probiotics are claimed to provide several health benefits such as improve lactose utilisation (De Vrese et al., 2001), prevent cancer (Rafter, 2003), maintain intestinal microflora balance (Mainville et al., 2005) and reduce serum cholesterol level (Baroutkoub et al., 2010). Moreover , yogurt containing Bifidobacterium bifidum Bb-12 improved immunoglobulin A (IgA) production in the intestine that enhances local immunity against gastrointestinal infection (Kabeerdoss et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The effects of Allium sativum and Cinnamomum verum water extracts on the survival of Bifidobacterium bifidum during 21 days of refrigerated storage and after simulated gastrointestinal digestion (SGD) were investigated. Two types of yogurt (cow- and camel-milk yogurts) were prepared in the presence of A. sativum or C. verum. The viable cell counts (VCC) of B. bifidum in fresh A. sativum- or C. verum-cow milk yogurt (1 day) were higher (8.1 × 109 cfu/ml and 6.6 × 109 cfu/ml, respectively; p < 0.05) than plain-yogurt (1.9 × 109 cfu/ml). In contrast, B. bifidum VCC in fresh plain-camel milk yogurt was 1.99 × 109 cfu/ml whereas the presence of A. sativum or C. verum in yogurt increased (p < 0.05) VCC to 19.61 × 109 cfu/ml and 25.55 × 109 cfu/ml, respectively. The VCC of B. bifidum in both herbal-yogurts decreased (p < 0.05) during refrigerated storage for both types of yogurt. The VCC of B. bifidum was ∼1.3 × 109 cfu/ml in all fresh cow milk yogurts after 1 h gastric digestion. Intestinal digestion (1 h) increased VCC of B. bifidum in all fresh yogurts but not in 7 day old yogurts (plain- and A. sativum-yogurts). However, prolonged digestion to another 1 h in intestine reduced (p < 0.05) VCC of B. bifidum in all fresh and storage yogurts. In contrast, all fresh camel milk yogurts showed VCC of B. bifidum ⩽1 × 109 cfu/ml after SGD. Seven day old A. sativum – camel milk yogurt showed the lowest survival of B. bifidum after gastric digestion compared to plain- and C. verum-yogurt. The VCC reduced (p < 0.05) in all camel milk-yogurts after 2 h intestinal digestion. In conclusion, A. sativum or C. verum water extract enhanced the growth of B. bifidum in both types of yogurt during refrigerated storage. However, these herbs did not influence B. bifidum survival after SGD.
    Journal of the Association of Arab Universities for Basic and Applied Sciences 03/2014; DOI:10.1016/j.jaubas.2014.02.006
  • Source
    • "The colon harbours several different microbiome constituents including both beneficial and harmful bacteria and the relative contribution of both types of organisms determines gut health status; however ingestion of probiotics can help to increase beneficial bacteria [Isolauri et al., 2002]. These bacteria influence carcinogenic processes through different mechanisms, and different bacterial strains have different mechanisms for their anticancer effects [Rafter, 2003]. A recent cohort study conducted over 12 years of follow-up on 45 241 volunteers found that intake of high yogurt was significantly linked with decreased CRC risk, suggesting that administration of long-term probiotics formulations can decrease the incidence of CRC [Pala et al., 2011]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The microbiome is a collection of all microbial species that coexist with an individual. These organisms influence several aspects of individual body functions. Probiotic organisms are generally beneficial components of microflora and confer normal health status. Usually, probiotics should be provided from the outside in the diet for maintaining proper health status. Probiotics can also have a significant impact on cancer management. While the results toward cancer management with probiotics are promising, careful risk assessment of probiotics use in cancer patients, who are usually immunocompromised due to radical therapy, comes as a great demand. This article provides an overview of the current research status of probiotics use in cancer patients and discusses the role of probiotics in cancer management. Drug Dev Res • • : • • – • • , 2013.
    Drug Development Research 09/2013; 74(6). DOI:10.1002/ddr.21087 · 0.77 Impact Factor
  • Source
    • "However, the composition of the gut microbiota is known to change transiently as a consequence of a variety of factors such as age, diet, enteral infections, pharmacological treatments and immunosuppression [7], [8], [9]. Changes in the microbiota composition have also been associated to several diseases, such as chronic inflammation of the GIT, diabetes and obesity [7], [10], [11], [12], [13], [14], and the oral administration of members of the microbiota has been considered as a potential clinical tool to relieve intestinal dysfunctions [15], [16], [17], [18], [19], [20]. Interest in the beneficial functions of the human microbiota has resulted in the selection of specific strains with putative health-promoting capacities that are recognized as probiotics and are generally selected from isolates of the Lactobacillus or Bifidobacterium species. "
    [Show abstract] [Hide abstract]
    ABSTRACT: It is now commonly accepted that the intestinal microbiota plays a crucial role in the gut physiology and homeostasis, and that both qualitative and quantitative alterations in the compositions of the gut flora exert profound effects on the host's intestinal cells. In spite of this, the details of the interaction between commensal bacteria and intestinal cells are still largely unknown and only in few cases the molecular mechanisms have been elucidated. Here we analyze the effects of molecules produced and secreted by Lactobacillus gasseri SF1183 on human intestinal HCT116 cells. L. gasseri is a well known species of lactic acid bacteria, commonly associated to the human intestine and SF1183 is a human strain previously isolated from an ileal biopsy of an healthy volunteer. SF1183 produces and secretes, in a growth phase-dependent way, molecule(s) able to drastically interfere with HCT116 cell proliferation. Although several attempts to purify and identify the bioactive molecule(s) have been so far unsuccessful, a partial characterization has indicated that it is smaller than 3 kDa, thermostable and of proteinaceous nature. L. gasseri molecule(s) stimulate a G1-phase arrest of the cell cycle by up-regulation of p21WAF1 rendering cells protected from intrinsic and extrinsic apoptosis. A L. gasseri-mediated reduction of apoptosis and of cell proliferation could be relevant in protecting epithelial barrier integrity and helping in reconstituting tissutal homeostasis.
    PLoS ONE 07/2013; 8(7):e69102. DOI:10.1371/journal.pone.0069102 · 3.23 Impact Factor
Show more